Welcome to the OMA Blog

Pediatric Obesity has become a global crisis, driving surge in type 2 diabetes among youth and threatening to overwhelm healthcare systems with early onset complications. This article explores the urgent need for a world-wide effort of research, legislative action, and community initiatives to tackle this impending public health disaster.

Metabolic associated liver disease (MASLD) is the most common chronic liver disease globally, linked to obesity and insulin resistance, with a growing prevalence in children. Early life factors such as maternal BMI, gestational diabetes, and breastfeeding play crucial roles in influencing the risk and progression of MASLD, highlighting the need for further research and preventive measures.

Highlighting Advocacy: Providing care to patients with obesity can be complex. The Obesity and Advocacy joint statement from the Obesity Medicine Association and the Obesity Action Coalition 2024 provides a clinical focus, an action-based framework, and a guide for health care providers.

Article Summary This article examines the incidence of slipped capital femoral epiphysis (SCFE) trends due to rising obesity rates. Healthcare providers need to monitor those pediatric patients that has the disease of obesity which is a compelling risk factor for developing SCFE along with hypothyroidism, osteodystrophy, or genetic predisposition. During this decade long study the incidence of SCFE surged from 2.46 to 5.96 per 10,000 children which according to the authors had a mirroring increase with childhood obesity trends. The authors analysis showed a similar concurrent rise of SCFE and obesity trends, however, they emphasized not trying to imply causality. Obesity is a major risk factor for developing SCFE in the pediatric population, which often presents with hip abnormalities.. The marked increase in SCFE during the same decade as the rise in obesity may indicate correlation between the two trends. The observation however did highlight one of the risk factors being obesity which could increase one’s risk of developing SCFE.

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. This month’s update refers to a systematic review of pharmacological interventions in children and adolescents with obesity.

This month’s update addresses treatment of hypothalamic obesity. Treatment of Hypothalamic Obesity in People with Hypothalamic Injury: New Drugs are on the Horizon Article Summary Hypothalamic obesity (HO) is a complex disorder resulting from either monogenic cause or injury of the hypothalamus. Read Full Article Article Review The article addresses the complex condition of hypothalamic obesity (HO). Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon.

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. 

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings. 

Each month, the OMA Pediatric Committee reviews a pediatric-focused obesity research update to help keep you up to date about the latest findings.